James Kim

Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 |
- CLINICAL TRIALS 1
- CONDITIONS2
- INTERVENTIONS1
- SINCE2010

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
August 2010 - July 2012
Multiple Myeloma
Neoplasms, Plasma Cell
Bt062



